A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Thyroid Neoplasms
Interventions
DRUG

Lenvatinib

Lenvatinib capsules.

Trial Locations (11)

110005

BL Kapoor Hospital, New Delhi, New Delhi

110029

All India Institute of Medical Sciences, New Delhi

110076

Indraprastha Apollo Hospital, New Delhi

334003

S. P. Medical College & A. G. Hospitals, Bikaner

400012

Tata Memorial Hospital, Mumbai

411004

Deenanath Mangeshkar Hospital, Pune

412105

Indrayani Hospital, Alandi, Pune

520002

City Cancer Centre, Vijayawada

560068

Shetty's Hospital, Bangalore

695011

Regional Cancer Centre, RCC, Thiruvananthapuram, Thiruvananthapuram

751019

All India Institute of Medical Sciences, Bhubaneshwar

All Listed Sponsors
lead

Eisai Pharmaceuticals India Pvt. Ltd

INDUSTRY